Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CFO Patrik Jeanmonod sold 3,500 shares of the business's stock in a transaction on Monday, September 26th. The stock was sold at an average price of $12.63, for a total transaction of $44,205.00. Following the completion of the sale, the chief financial officer now directly owns 89,063 shares in the company, valued at approximately $1,124,865.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Patrik Jeanmonod also recently made the following trade(s):

• On Wednesday, August 24th, Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock. The stock was sold at an average price of $13.45, for a total transaction of $47,075.00.
• On Monday, August 1st, Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock. The stock was sold at an average price of $12.80, for a total transaction of $44,800.00.

Cytek Biosciences Trading Up 11.4 %

Shares of NASDAQ:CTKB traded up $1.45 on Wednesday, hitting $14.19. The company had a trading volume of 661,872 shares, compared to its average volume of 858,285. Cytek Biosciences, Inc. has a 1-year low of $7.38 and a 1-year high of $26.50. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -701.50 and a beta of 0.53. The stock has a 50 day moving average price of $13.25 and a 200 day moving average price of $11.38.

Hedge Funds Weigh In On Cytek Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CTKB. Parkwood LLC grew its stake in shares of Cytek Biosciences by 44.3% in the second quarter. Parkwood LLC now owns 42,292 shares of the company's stock valued at $42,000 after acquiring an additional 12,981 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Cytek Biosciences by 64.1% in the first quarter. Royal Bank of Canada now owns 5,995 shares of the company's stock valued at $65,000 after acquiring an additional 2,341 shares in the last quarter. Metropolitan Life Insurance Co NY grew its stake in shares of Cytek Biosciences by 31.5% in the first quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock valued at $69,000 after acquiring an additional 1,536 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Cytek Biosciences in the second quarter valued at about $70,000. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Cytek Biosciences by 514.7% in the first quarter. Ameritas Investment Partners Inc. now owns 7,567 shares of the company's stock valued at $82,000 after acquiring an additional 6,336 shares in the last quarter. 43.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CTKB. Piper Sandler upped their price target on shares of Cytek Biosciences from $12.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 17th. Morgan Stanley upped their price target on shares of Cytek Biosciences from $11.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Friday, August 12th. Finally, The Goldman Sachs Group upped their price target on shares of Cytek Biosciences from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th.

Cytek Biosciences Company Profile

(Get Rating)

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.

Featured Articles

• Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
• Can United Natural Foods Fight Both Inflation and the Fed?
• Mullen Automotive Is Ready To Get In Gear
• Cracker Barrel: A Tasty Treat Or Bad Apple?
• Defensive Stocks For A Volatile Market
• Will UPS Be Next to Deliver a Warning?

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.